Evidence map›Paper›PMID 33921166›Full record

ArticleMicroorganisms2021

Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial.

Eric Climent, Juan Francisco Martinez-Blanch, Laura Llobregat, Beatriz Ruzafa-Costas, Miguel Ángel Carrión-Gutiérrez, Ana Ramírez-Boscá, David Prieto-Merino, Salvador Genovés, Francisco M Codoñer, Daniel Ramón and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719649 (The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719649 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial

TypeinterventionalSponsorSunWay Biotech Co., LTD.Ran2023 to 2023Enrolled72ConditionsAtopic Dermatitis, Atopic Dermatitis EczemaArmsLactic acid bacteria NTU 101, Placebo
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 39 citations in OpenAlex.

  1. Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. The results of the ProPAD trial.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022
    Trial
  2. Article
  3. Review
  4. Extracellular vesicles ofGut microbes · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Eric ClimentBiopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif. 2, 46980 Paterna, Spain.ORCID 0000-0001-6372-8371
Juan Francisco Martinez-BlanchBiopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif. 2, 46980 Paterna, Spain.ORCID 0000-0002-9340-6207
Laura LlobregatBiopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif. 2, 46980 Paterna, Spain.
Beatriz Ruzafa-CostasDepartment of Clinical Medicine, Universidad Católica San Antonio de Murcia (UCAM), 30107 Murcia, Spain.
Miguel Ángel Carrión-GutiérrezEspecialida des Farmacéuticas Centrum, Calle Sagitario 14, 03006 Alicante, Spain.
Ana Ramírez-BoscáDepartment of Clinical Medicine, Universidad Católica San Antonio de Murcia (UCAM), 30107 Murcia, Spain.
David Prieto-MerinoApplied Statistical Methods in Medical Research Group, Universidad Católica San Antonio de Murcia (UCAM), 30107 Murcia, Spain.ORCID 0000-0001-5001-0061
Salvador GenovésBiopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif. 2, 46980 Paterna, Spain.
Francisco M CodoñerBiopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif. 2, 46980 Paterna, Spain.
Daniel RamónBiopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif. 2, 46980 Paterna, Spain.
Empar ChenollBiopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif. 2, 46980 Paterna, Spain.ORCID 0000-0002-6891-3573
Vicente Navarro-LópezDepartment of Clinical Medicine, Universidad Católica San Antonio de Murcia (UCAM), 30107 Murcia, Spain.ORCID 0000-0001-9785-523X
Biopolis (Spain) · ESHospital Universitario del Vinalopó · ESLondon School of Hygiene & Tropical Medicine · GBUniversidad Católica de Murcia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease with a high impact on the comfort of those who are affected and long-term treated with corticosteroids with limited efficacy and a high prevalence of relapses. Because of the limited effectiveness of these treatments, new strategies for recovery from AD lesions are continually being explored. In this article, we describe the gut microbiome changes achieved in a recently published clinical trial with the probiotic formulation

Indexed as

atopic dermatitisBifidobacteriumFaecalibacteriumgut-skin axismicrobiomeprobiotics

Identifiers

PMID33921166
PMCPMC8071520
OpenAlexW3155051569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.